Report : North America Immunodiagnostic Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product [Enzyme-Linked Immunosorbent Assays, Chemiluminescence Immunoassays (Vitamin D Assay, HIV Detection, HIV Ag/Ab Combo Assay, and Others), Radioimmunoassays, and Others], Clinical Indication [Infectious Diseases (COVID-19, Lyme, Zika, Infection Management, TORCH, Tuberculosis, Treponema, Measles & Mumps, EBV, and VZV), Hepatitis+HIV, Gastrointestinal, Metabolics , Endocrinology (Hypertension, GROWTH, Diabetes, Thyroid, and Reproductive Endocrinology), and Others], and End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others)
Enzyme-Linked Immunosorbent Assays Segment to Dominate North America Immunodiagnostic Market
According to our new research study, titled "North America Immunodiagnostic Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product, Clinical Indication, and End User," the North America immunodiagnostic market is projected to grow from US$ 9,188.19 million in 2021 to US$ 15,040.40 million by 2028; it is estimated to grow at a CAGR of 7.3% from 2022 to 2028. The market growth is primarily attributed to the increasing prevalence of infectious diseases and the growing use of point-of-care immunodiagnostics. However, the inadequate reimbursement scenario is hindering the growth of the market.
The report segments the North America immunodiagnostic market as follows:
Based on product, North America immunodiagnostic market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. The chemiluminescence immunoassay (CLIA) is further categorized into Vitamin D assay, HIV detection, HIV Ag/Ab Combo assay, and others. The enzyme-linked immunosorbent assays (ELISA) segment held the largest share of the market in 2021. However, the chemiluminescence immunoassay (CLIA) segment is expected to grow at the highest CAGR during the forecast period. Advancements in the ELISA technique have led to the development of quantitative PCR, fluorogenic, and electrochemiluminescent reporters that are used to generate signals. Also, the nanotechnology boom has yielded some developments supporting the designing of nanomaterial-based improved ELISA in recent years. The ELISA and lateral flow immunoassay were widely used during COVID-19 for the identification of individuals having antibodies developed against SARS-CoV-2. ELISA is the most used classical serological test, with an average detection time of 2–8 hours.
Based on clinical indication, North America immunodiagnostic market is segmented into infectious diseases, hepatitis+HIV, gastrointestinal, metabolic diseases, endocrinology, and others. The infectious disease segment is further divided into COVID-19, Tuberculosis, Lyme, Infection Management, Zika, Treponema, TORCH, Measles and Mumps, VZV, and EBV. The infectious diseases segment held the largest share of the market in 2021 and is further anticipated to register the highest CAGR during the forecast period. Many potential target biomarkers, as well as combinations of biomarkers, are available for the detection of infectious diseases. Immunodiagnostics complements molecular assays in the study of infectious diseases. There are many immunodiagnostic tests that can be used to assist in the diagnosis of infectious, endocrine, and neoplastic diseases as well as to measure blood drug concentrations.
Based on end user, the immunodiagnostic market is segmented into hospitals, clinics, diagnostics laboratories, academic and research institutes, and others. The hospitals segment held the largest share of the market in 2021. However, the clinics segment is anticipated to register the highest CAGR during the forecast period. The immunodiagnostics test segment is performed in different hospitals departments, including clinical microbiology departments, pathological labs, serological labs, histopathology and hematology section, clinical biochemistry laboratories, and hospital wards. Some immunodiagnostics instruments give quick results, while in the case of complex tests, the samples are sent to specialized laboratories. Various tests performed in hospitals include enzyme-linked immunosorbent assays, Western Blot, and infectious disease diagnosis tests.
On the basis of country, the immunodiagnostic market is segmented into the US, Canada, and Mexico. ABBOTT; PerkinElmer Inc.; bioMérieux SA; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthineers AG; Thermo Fisher Scientific Inc; Danaher Corp; DiaSorin S.p.A.; and F. Hoffmann-La Roche Ltd. are among the key companies operating in the North America immunodiagnostics market.